CD274 and neoplasm: One of the noteworthy findings of this trial is that the response rate for pembrolizumab was higher in the low PD-L1 tumor proportion score group and the high PD-L1 mononuclear inflammatory cell density score group than in the groups that had high and low scores, respectively, on these measures.